Skip to main content
. 2023 Jan 10;9:1029040. doi: 10.3389/fmed.2022.1029040

FIGURE 2.

FIGURE 2

(A) Market shares (%) of biosimilar TNF-alpha inhibitors in Portugal. Data at the national/regional level are provided for infliximab (2016–2021), etanercept (2017–2021), and adalimumab biosimilars (2018–2021). (B) Geographical location of low-(<50%), intermediate-(50–75%), and high-uptake (>75%) regions for TNF-alpha inhibitors in Portugal. (C) List of Portuguese health areas sorted in increasing order of biosimilars uptake (%).